KONINKLIJKE PHILIPS NV (PHI1.DE) Fundamental Analysis & Valuation

FRA:PHI1 • NL0000009538

Current stock price

22.38 EUR
+0.47 (+2.15%)
Last:

This PHI1.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

4

1. PHI1.DE Profitability Analysis

1.1 Basic Checks

  • PHI1 had positive earnings in the past year.
  • In the past year PHI1 had a positive cash flow from operations.
  • The reported net income has been mixed in the past 5 years: PHI1 reported negative net income in multiple years.
  • Of the past 5 years PHI1 4 years had a positive operating cash flow.
PHI1.DE Yearly Net Income VS EBIT VS OCF VS FCFPHI1.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2B 4B

1.2 Ratios

  • PHI1 has a Return On Assets of 3.32%. This is comparable to the rest of the industry: PHI1 outperforms 50.00% of its industry peers.
  • With a decent Return On Equity value of 8.17%, PHI1 is doing good in the industry, outperforming 60.34% of the companies in the same industry.
  • PHI1's Return On Invested Capital of 5.16% is in line compared to the rest of the industry. PHI1 outperforms 50.00% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for PHI1 is significantly below the industry average of 9.41%.
  • The 3 year average ROIC (3.27%) for PHI1 is below the current ROIC(5.16%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 3.32%
ROE 8.17%
ROIC 5.16%
ROA(3y)-0.23%
ROA(5y)0.96%
ROE(3y)-0.52%
ROE(5y)1.86%
ROIC(3y)3.27%
ROIC(5y)N/A
PHI1.DE Yearly ROA, ROE, ROICPHI1.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 -10 20

1.3 Margins

  • PHI1 has a Profit Margin of 5.02%. This is comparable to the rest of the industry: PHI1 outperforms 50.00% of its industry peers.
  • In the last couple of years the Profit Margin of PHI1 has declined.
  • PHI1 has a Operating Margin of 7.98%. This is comparable to the rest of the industry: PHI1 outperforms 48.28% of its industry peers.
  • PHI1's Operating Margin has declined in the last couple of years.
  • PHI1's Gross Margin of 45.18% is on the low side compared to the rest of the industry. PHI1 is outperformed by 72.41% of its industry peers.
  • In the last couple of years the Gross Margin of PHI1 has remained more or less at the same level.
Industry RankSector Rank
OM 7.98%
PM (TTM) 5.02%
GM 45.18%
OM growth 3YN/A
OM growth 5Y-5.27%
PM growth 3YN/A
PM growth 5Y-6.05%
GM growth 3Y3.66%
GM growth 5Y-0.43%
PHI1.DE Yearly Profit, Operating, Gross MarginsPHI1.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 20 30 40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. PHI1.DE Health Analysis

2.1 Basic Checks

  • PHI1 has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • Compared to 1 year ago, PHI1 has more shares outstanding
  • Compared to 5 years ago, PHI1 has more shares outstanding
  • The debt/assets ratio for PHI1 is higher compared to a year ago.
PHI1.DE Yearly Shares OutstandingPHI1.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M
PHI1.DE Yearly Total Debt VS Total AssetsPHI1.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10B 20B 30B

2.2 Solvency

  • An Altman-Z score of 1.92 indicates that PHI1 is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • PHI1 has a Altman-Z score of 1.92. This is comparable to the rest of the industry: PHI1 outperforms 43.10% of its industry peers.
  • PHI1 has a debt to FCF ratio of 16.37. This is a negative value and a sign of low solvency as PHI1 would need 16.37 years to pay back of all of its debts.
  • PHI1 has a Debt to FCF ratio (16.37) which is in line with its industry peers.
  • PHI1 has a Debt/Equity ratio of 0.63. This is a neutral value indicating PHI1 is somewhat dependend on debt financing.
  • PHI1 has a worse Debt to Equity ratio (0.63) than 72.41% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.63
Debt/FCF 16.37
Altman-Z 1.92
ROIC/WACC0.85
WACC6.1%
PHI1.DE Yearly LT Debt VS Equity VS FCFPHI1.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5B 10B

2.3 Liquidity

  • A Current Ratio of 1.32 indicates that PHI1 should not have too much problems paying its short term obligations.
  • With a Current ratio value of 1.32, PHI1 is not doing good in the industry: 63.79% of the companies in the same industry are doing better.
  • A Quick Ratio of 0.94 indicates that PHI1 may have some problems paying its short term obligations.
  • The Quick ratio of PHI1 (0.94) is worse than 63.79% of its industry peers.
Industry RankSector Rank
Current Ratio 1.32
Quick Ratio 0.94
PHI1.DE Yearly Current Assets VS Current LiabilitesPHI1.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. PHI1.DE Growth Analysis

3.1 Past

  • PHI1 shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 6.11%.
  • Measured over the past years, PHI1 shows a decrease in Earnings Per Share. The EPS has been decreasing by -6.62% on average per year.
  • PHI1 shows a decrease in Revenue. In the last year, the revenue decreased by -1.03%.
  • Measured over the past years, PHI1 shows a small growth in Revenue. The Revenue has been growing by 0.59% on average per year.
EPS 1Y (TTM)6.11%
EPS 3Y15.66%
EPS 5Y-6.62%
EPS Q2Q%-1.96%
Revenue 1Y (TTM)-1.03%
Revenue growth 3Y0.01%
Revenue growth 5Y0.59%
Sales Q2Q%1.05%

3.2 Future

  • PHI1 is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.00% yearly.
  • Based on estimates for the next years, PHI1 will show a small growth in Revenue. The Revenue will grow by 3.47% on average per year.
EPS Next Y3.11%
EPS Next 2Y8.19%
EPS Next 3Y10.16%
EPS Next 5Y10%
Revenue Next Year1.44%
Revenue Next 2Y2.95%
Revenue Next 3Y3.5%
Revenue Next 5Y3.47%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
PHI1.DE Yearly Revenue VS EstimatesPHI1.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 5B 10B 15B 20B 25B
PHI1.DE Yearly EPS VS EstimatesPHI1.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0.5 1 1.5 2

More info and screens

Find the best growth stocksShow best growing peers

4

4. PHI1.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 15.22 indicates a correct valuation of PHI1.
  • Based on the Price/Earnings ratio, PHI1 is valued cheaper than 87.93% of the companies in the same industry.
  • PHI1 is valuated rather cheaply when we compare the Price/Earnings ratio to 26.77, which is the current average of the S&P500 Index.
  • The Price/Forward Earnings ratio is 14.76, which indicates a correct valuation of PHI1.
  • PHI1's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. PHI1 is cheaper than 65.52% of the companies in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 21.75, PHI1 is valued a bit cheaper.
Industry RankSector Rank
PE 15.22
Fwd PE 14.76
PHI1.DE Price Earnings VS Forward Price EarningsPHI1.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • 72.41% of the companies in the same industry are more expensive than PHI1, based on the Enterprise Value to EBITDA ratio.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of PHI1 is on the same level as its industry peers.
Industry RankSector Rank
P/FCF 43.62
EV/EBITDA 10.35
PHI1.DE Per share dataPHI1.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
PEG (NY)4.89
PEG (5Y)N/A
EPS Next 2Y8.19%
EPS Next 3Y10.16%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. PHI1.DE Dividend Analysis

5.1 Amount

  • No dividends for PHI1!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

PHI1.DE Fundamentals: All Metrics, Ratios and Statistics

KONINKLIJKE PHILIPS NV

FRA:PHI1 (4/30/2026, 7:00:00 PM)

22.38

+0.47 (+2.15%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Industry Strength38.51
Industry Growth70
Earnings (Last)02-10
Earnings (Next)05-06
Inst Owners48.33%
Inst Owner ChangeN/A
Ins Owners0.04%
Ins Owner ChangeN/A
Market Cap21.55B
Revenue(TTM)17.84B
Net Income(TTM)895.00M
Analysts74.67
Price Target29.06 (29.85%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0.35
Dividend Growth(5Y)216.55%
DP36.65%
Div Incr Years0
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)9.02%
Min EPS beat(2)3.95%
Max EPS beat(2)14.1%
EPS beat(4)4
Avg EPS beat(4)17.83%
Min EPS beat(4)3.95%
Max EPS beat(4)31.04%
EPS beat(8)4
Avg EPS beat(8)2.84%
EPS beat(12)6
Avg EPS beat(12)6.47%
EPS beat(16)7
Avg EPS beat(16)6.93%
Revenue beat(2)0
Avg Revenue beat(2)-1.63%
Min Revenue beat(2)-2.4%
Max Revenue beat(2)-0.86%
Revenue beat(4)0
Avg Revenue beat(4)-1.8%
Min Revenue beat(4)-2.4%
Max Revenue beat(4)-0.86%
Revenue beat(8)0
Avg Revenue beat(8)-2.61%
Revenue beat(12)1
Avg Revenue beat(12)-2.36%
Revenue beat(16)2
Avg Revenue beat(16)-1.72%
PT rev (1m)-0.78%
PT rev (3m)7.34%
EPS NQ rev (1m)-4.65%
EPS NQ rev (3m)-24.01%
EPS NY rev (1m)-0.89%
EPS NY rev (3m)-0.39%
Revenue NQ rev (1m)-0.63%
Revenue NQ rev (3m)2.22%
Revenue NY rev (1m)0.14%
Revenue NY rev (3m)-1.26%
Valuation
Industry RankSector Rank
PE 15.22
Fwd PE 14.76
P/S 1.21
P/FCF 43.62
P/OCF 18.55
P/B 1.97
P/tB N/A
EV/EBITDA 10.35
EPS(TTM)1.47
EY6.57%
EPS(NY)1.52
Fwd EY6.77%
FCF(TTM)0.51
FCFY2.29%
OCF(TTM)1.21
OCFY5.39%
SpS18.52
BVpS11.38
TBVpS-0.92
PEG (NY)4.89
PEG (5Y)N/A
Graham Number19.4007 (-13.31%)
Profitability
Industry RankSector Rank
ROA 3.32%
ROE 8.17%
ROCE 7.33%
ROIC 5.16%
ROICexc 6.02%
ROICexgc 20.88%
OM 7.98%
PM (TTM) 5.02%
GM 45.18%
FCFM 2.77%
ROA(3y)-0.23%
ROA(5y)0.96%
ROE(3y)-0.52%
ROE(5y)1.86%
ROIC(3y)3.27%
ROIC(5y)N/A
ROICexc(3y)3.74%
ROICexc(5y)N/A
ROICexgc(3y)12.88%
ROICexgc(5y)N/A
ROCE(3y)4.66%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5Y-1.19%
ROICexc growth 3YN/A
ROICexc growth 5Y-4.56%
OM growth 3YN/A
OM growth 5Y-5.27%
PM growth 3YN/A
PM growth 5Y-6.05%
GM growth 3Y3.66%
GM growth 5Y-0.43%
F-Score7
Asset Turnover0.66
Health
Industry RankSector Rank
Debt/Equity 0.63
Debt/FCF 16.37
Debt/EBITDA 2.72
Cap/Depr 59.38%
Cap/Sales 3.75%
Interest Coverage 5.63
Cash Conversion 45.59%
Profit Quality 55.2%
Current Ratio 1.32
Quick Ratio 0.94
Altman-Z 1.92
F-Score7
WACC6.1%
ROIC/WACC0.85
Cap/Depr(3y)53.03%
Cap/Depr(5y)53.41%
Cap/Sales(3y)3.68%
Cap/Sales(5y)4%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)6.11%
EPS 3Y15.66%
EPS 5Y-6.62%
EPS Q2Q%-1.96%
EPS Next Y3.11%
EPS Next 2Y8.19%
EPS Next 3Y10.16%
EPS Next 5Y10%
Revenue 1Y (TTM)-1.03%
Revenue growth 3Y0.01%
Revenue growth 5Y0.59%
Sales Q2Q%1.05%
Revenue Next Year1.44%
Revenue Next 2Y2.95%
Revenue Next 3Y3.5%
Revenue Next 5Y3.47%
EBIT growth 1Y15922.2%
EBIT growth 3YN/A
EBIT growth 5Y-4.71%
EBIT Next Year68.02%
EBIT Next 3Y26.32%
EBIT Next 5Y17.82%
FCF growth 1Y-43.86%
FCF growth 3YN/A
FCF growth 5Y-22.31%
OCF growth 1Y-25.32%
OCF growth 3YN/A
OCF growth 5Y-15.14%

KONINKLIJKE PHILIPS NV / PHI1.DE Fundamental Analysis FAQ

What is the ChartMill fundamental rating of KONINKLIJKE PHILIPS NV (PHI1.DE) stock?

ChartMill assigns a fundamental rating of 3 / 10 to PHI1.DE.


What is the valuation status for PHI1 stock?

ChartMill assigns a valuation rating of 4 / 10 to KONINKLIJKE PHILIPS NV (PHI1.DE). This can be considered as Fairly Valued.


What is the profitability of PHI1 stock?

KONINKLIJKE PHILIPS NV (PHI1.DE) has a profitability rating of 4 / 10.


What is the financial health of KONINKLIJKE PHILIPS NV (PHI1.DE) stock?

The financial health rating of KONINKLIJKE PHILIPS NV (PHI1.DE) is 2 / 10.


Can you provide the expected EPS growth for PHI1 stock?

The Earnings per Share (EPS) of KONINKLIJKE PHILIPS NV (PHI1.DE) is expected to grow by 3.11% in the next year.